291 related articles for article (PubMed ID: 36327160)
21. [CAR-T therapy for multiple myeloma].
Ri M
Rinsho Ketsueki; 2023; 64(11):1456-1464. PubMed ID: 38072434
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].
Ge J; Zhao TT; Wan CY; Xia JY; Guo SY; Yu MX; Chen J; Wang Y; Xu KL; Li ZY
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):733-738. PubMed ID: 34753227
[No Abstract] [Full Text] [Related]
23. Sequence not salvage.
Sborov DW; Fortuna GG; Hayden PJ
Br J Haematol; 2024 May; 204(5):1590-1592. PubMed ID: 38563345
[TBL] [Abstract][Full Text] [Related]
24. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
Zhao WH; Liu J; Wang BY; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Yang N; Zhang R; Zhang H; Shen Y; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Li ZF; Li ZZ; Geng Y; He Q; Zhuang QC; Fan XH; He AL; Zhang WG
J Hematol Oncol; 2018 Dec; 11(1):141. PubMed ID: 30572922
[TBL] [Abstract][Full Text] [Related]
25. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
26. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
Yan L; Qu S; Shang J; Shi X; Kang L; Xu N; Zhu M; Zhou J; Jin S; Yao W; Yao Y; Chen G; Chang H; Zhu X; Yu L; Wu D; Fu C
Cancer Med; 2021 Jan; 10(2):563-574. PubMed ID: 33356013
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
28. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
Gagelmann N; Ayuk F; Atanackovic D; Kröger N
Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
[TBL] [Abstract][Full Text] [Related]
29. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
Pont MJ; Hill T; Cole GO; Abbott JJ; Kelliher J; Salter AI; Hudecek M; Comstock ML; Rajan A; Patel BKR; Voutsinas JM; Wu Q; Liu L; Cowan AJ; Wood BL; Green DJ; Riddell SR
Blood; 2019 Nov; 134(19):1585-1597. PubMed ID: 31558469
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
Zhang L; Shen X; Yu W; Li J; Zhang J; Zhang R; Li J; Chen L
Ann Med; 2021 Dec; 53(1):1547-1559. PubMed ID: 34459681
[TBL] [Abstract][Full Text] [Related]
31. Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
Martin TG; Madduri D; Pacaud L; Usmani SZ
Future Oncol; 2023 Nov; 19(34):2297-2311. PubMed ID: 37497629
[TBL] [Abstract][Full Text] [Related]
32. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.
Shi M; Wang J; Huang H; Liu D; Cheng H; Wang X; Chen W; Yan Z; Sang W; Qi K; Li D; Zhu F; Li Z; Qiao J; Wu Q; Zeng L; Fei X; Gu W; Miao Y; Xu K; Zheng J; Cao J
Nat Commun; 2024 Apr; 15(1):3371. PubMed ID: 38643278
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.
Zhao G; Wei R; Feng L; Wu Y; He F; Xiao M; Cheng Z
Cancer Immunol Immunother; 2022 Jan; 71(1):39-44. PubMed ID: 34003300
[TBL] [Abstract][Full Text] [Related]
34. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
Wu JF; Dhakal B
J Hematol Oncol; 2023 Jul; 16(1):86. PubMed ID: 37507805
[TBL] [Abstract][Full Text] [Related]
35. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
[TBL] [Abstract][Full Text] [Related]
36. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Oliver-Caldés A; González-Calle V; Cabañas V; Español-Rego M; Rodríguez-Otero P; Reguera JL; López-Corral L; Martin-Antonio B; Zabaleta A; Inogés S; Varea S; Rosiñol L; López-Díaz de Cerio A; Tovar N; Jiménez R; López-Parra M; Rodríguez-Lobato LG; Sánchez-Salinas A; Olesti E; Calvo-Orteu M; Delgado J; Pérez-Simón JA; Paiva B; Prósper F; Sáez-Peñataro J; Juan M; Moraleda JM; Mateos MV; Pascal M; Urbano-Ispizua A; Fernández de Larrea C
Lancet Oncol; 2023 Aug; 24(8):913-924. PubMed ID: 37414060
[TBL] [Abstract][Full Text] [Related]
37. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy.
Kambhampati S; Sheng Y; Huang CY; Bylsma S; Lo M; Kennedy V; Natsuhara K; Martin T; Wolf J; Shah N; Wong SW
Blood Adv; 2022 Apr; 6(7):2045-2054. PubMed ID: 34543400
[TBL] [Abstract][Full Text] [Related]
38. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.
Díez-Alonso L; Falgas A; Arroyo-Ródenas J; Romencín PA; Martínez A; Gómez-Rosel M; Blanco B; Jiménez-Reinoso A; Mayado A; Pérez-Pons A; Aguilar-Sopeña Ó; Ramírez-Fernández Á; Segura-Tudela A; Perez-Amill L; Tapia-Galisteo A; Domínguez-Alonso C; Rubio-Pérez L; Jara M; Solé F; Hangiu O; Almagro L; Albitre Á; Penela P; Sanz L; Anguita E; Valeri A; García-Ortiz A; Río P; Juan M; Martínez-López J; Roda-Navarro P; Martín-Antonio B; Orfao A; Menéndez P; Bueno C; Álvarez-Vallina L
Sci Transl Med; 2024 Feb; 16(734):eadg7962. PubMed ID: 38354229
[TBL] [Abstract][Full Text] [Related]
39. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Gagelmann N; Dima D; Merz M; Hashmi H; Ahmed N; Tovar N; Oliver-Caldés A; Stölzel F; Rathje K; Fischer L; Born P; Schäfer L; Albici AM; Schub N; Kfir-Erenfeld S; Assayag M; Asherie N; Wulf GG; Kharboutli S; Müller F; Shune L; Davis JA; Anwer F; Vucinic V; Platzbecker U; Ayuk F; Kröger N; Khouri J; Gurnari C; McGuirk J; Stepensky P; Abdallah AO; Fernández de Larrea C
J Clin Oncol; 2024 May; 42(14):1665-1675. PubMed ID: 38358946
[TBL] [Abstract][Full Text] [Related]
40. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.
Zhang Q; Zu C; Jing R; Feng Y; Zhang Y; Zhang M; Lv Y; Cui J; Zhou L; Meng Y; Wang L; Cen Z; Chang AH; Hu Y; Huang H
Front Immunol; 2023; 14():1125357. PubMed ID: 37215107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]